Grant: Engage Grants Program
McGill University
$25,000.00
Prototyping and Validation of Intervertebral Disc Bioreactors with Complex Loading Capacities
EF 2019-20
Résumé
Low back pain (LBP) is tiredness, discomfort or pain in the low back, which leads to the medical expenditure of $12 billion annually in Canada. Clinical evidence has linked LBP with intervertebral disc (IVD) degeneration that often requires surgical intervention due to the lack of healing capacity of native IVD. There are a variety of implantable biomaterials under development for IVD repair. However, the development has been long bottlenecked by the lack of IVD bioreactors capable of reproducing the in vivo conditions in a laboratory setting. This project is focused on design, fabrication, and validation of a novel bioreactor for IVD studies. Such a device is designed to combine the capacity of compression, bending and torsion loading simultaneously, while is fully compatible with whole organ culture ex vivo. This project would directly address a critical need of a Canadian company for the development and validation of hydrogel implants for IVD repair. The device can enable high-throughput safety and efficacy evaluation of IVD implants, and mitigate the need of lengthy and expensive animal experiments. This project will address the need of the company, set the foundation for its follow-up collaboration with the PI, and ultimately help improve the healthcare of millions of patients living with IVD diseases.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
538388-2019
Name nom
Li, Jianyu
Department département
Mechanical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Prototyping and Validation of Intervertebral Disc Bioreactors with Complex Loading Capacities
Keyword
NSERC
Application summary
Low back pain (LBP) is tiredness, discomfort or pain in the low back, which leads to the medical expenditure of $12 billion annually in Canada. Clinical evidence has linked LBP with intervertebral disc (IVD) degeneration that often requires surgical intervention due to the lack of healing capacity of native IVD. There are a variety of implantable biomaterials under development for IVD repair. However, the development has been long bottlenecked by the lack of IVD bioreactors capable of reproducing the in vivo conditions in a laboratory setting. This project is focused on design, fabrication, and validation of a novel bioreactor for IVD studies. Such a device is designed to combine the capacity of compression, bending and torsion loading simultaneously, while is fully compatible with whole organ culture ex vivo. This project would directly address a critical need of a Canadian company for the development and validation of hydrogel implants for IVD repair. The device can enable high-throughput safety and efficacy evaluation of IVD implants, and mitigate the need of lengthy and expensive animal experiments. This project will address the need of the company, set the foundation for its follow-up collaboration with the PI, and ultimately help improve the healthcare of millions of patients living with IVD diseases.